USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Academisch Ziekenhuis Leiden (H.O.D.N. LUMC) GMBH

USPTO PatentsView assignee record - 67 granted patents across 23 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company

The verdict

According to USPTO PatentsView, Academisch ranks #5,134 of 49,997 tracked US assignees by granted-patent volume, with 67 patents across 23 technology areas.

#5,134
of 49,997 US assignees by volume
Top 24%
by Innovation Score (45.1/100)
15.4
avg claims per patent
-32%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5134 · Foreign Corporation #5,134 · 67 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-SMALL 67 grants
  • UPPER-Q #5,134/49,997
  • PHOTO-FINISH AAC Optics (Suzhou)
  • CPC-FOCUS A61P · 23 areas
  • INNOV-PAR 45.1/100
  • CLAIMS-RICH 15.4 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DOWN -32% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: AAC Optics (Suzhou) Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Academisch

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Academisch's Innovation Score is 45.1/100 (top 24% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Academisch's grants concentrate

Academisch Ziekenhuis Leiden (H.O.D.N. LUMC) GMBH is a focused PatentsView assignee: 23 CPC subclasses with 70.1% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (9 grants) versus a trough of 4 in 2015. By volume, Academisch sits between emz-Hanauer GmbH & Co. KGaA and Amini Innovation Corporation.

Academisch's three-year grant acceleration

From 2019–2021 to 2022–2024, Academisch Ziekenhuis Leiden (H.O.D.N. LUMC) GMBH moved from 20 to 13 grants (0.65x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Who files at Academisch's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Academisch holds 67 patents at rank #5,134, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Academisch

By rank, the assignees closest to #5,134 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Academisch's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Academisch, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Academisch ranks #383 of 6,058 assignees by patent count in that subclass.

Academisch's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 24% higher than 76% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

246810 20152016201720182019202020212022202320242025 5
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Academisch Ziekenhuis Leiden (H.O.D.N. LUMC) GMBH patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 4 6.0%
2016 8 11.9%
2017 8 11.9%
2018 9 13.4%
2019 8 11.9%
2020 8 11.9%
2021 4 6.0%
2022 5 7.5%
2023 4 6.0%
2024 4 6.0%
2025partial year 5 7.5%

Which technologies does Academisch Ziekenhuis Leiden (H.O.D.N. LUMC) GMBH patent most?

Top 15 of 23 technology areas

Where it ranks

Overall rank by patents

#5,134

of 49,997 tracked assignees

Innovation Score

45.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Academisch Ziekenhuis Leiden (H.O.D.N. LUMC) GMBH's patent record in context - here's where to go next.

  • Academisch Ziekenhuis Leiden (H.O.D.N. LUMC) GMBH's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 70.1% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #5,134 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Academisch Ziekenhuis Leiden (H.O.D.N. LUMC) GMBH against emz-Hanauer GmbH & Co. KGaA, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 45.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.